XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 135 filers reported holding XENON PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 10.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $13,301,517 | -7.9% | 341,152 | +1.6% | 0.00% | – |
Q1 2024 | $14,449,086 | -3.0% | 335,635 | +3.8% | 0.00% | – |
Q4 2023 | $14,900,180 | +63.5% | 323,495 | +21.2% | 0.00% | – |
Q3 2023 | $9,114,775 | -9.4% | 266,826 | +2.1% | 0.00% | – |
Q2 2023 | $10,062,091 | +12.7% | 261,353 | +4.8% | 0.00% | – |
Q1 2023 | $8,924,380 | +17.8% | 249,354 | +29.8% | 0.00% | – |
Q4 2022 | $7,573,557 | +13.3% | 192,076 | +3.7% | 0.00% | – |
Q3 2022 | $6,686,000 | +19.6% | 185,192 | +0.7% | 0.00% | – |
Q2 2022 | $5,592,000 | +11.9% | 183,845 | +12.5% | 0.00% | – |
Q1 2022 | $4,997,000 | +4.3% | 163,468 | +6.6% | 0.00% | – |
Q4 2021 | $4,792,000 | +192.6% | 153,366 | +43.1% | 0.00% | – |
Q3 2021 | $1,638,000 | -15.0% | 107,192 | +3.6% | 0.00% | – |
Q2 2021 | $1,926,000 | +0.7% | 103,436 | -3.1% | 0.00% | – |
Q1 2021 | $1,912,000 | +27.5% | 106,795 | +9.5% | 0.00% | – |
Q4 2020 | $1,500,000 | +42.7% | 97,563 | +2.8% | 0.00% | – |
Q3 2020 | $1,051,000 | -11.6% | 94,893 | +0.2% | 0.00% | – |
Q2 2020 | $1,189,000 | – | 94,743 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,754,266 | $107,388,831 | 7.33% |
Altium Capital Management LP | 360,600 | $14,059,794 | 5.74% |
Affinity Asset Advisors, LLC | 994,227 | $38,764,911 | 4.47% |
First Light Asset Management, LLC | 1,306,260 | $50,931,077 | 4.46% |
Nan Fung Group Holdings Ltd | 106,680 | $4,159,453 | 4.44% |
Ally Bridge Group (NY) LLC | 169,369 | $6,603,697 | 3.93% |
TLS Advisors LLC | 32,956 | $1,285 | 3.22% |
BRAIDWELL LP | 2,560,573 | $99,836,741 | 3.13% |
Paradigm Biocapital Advisors LP | 2,043,280 | $79,667,487 | 3.05% |
BRIDGER MANAGEMENT, LLC | 146,800 | $5,723,732 | 2.94% |